REPL
Replimune Group, Inc.
Biotechnology
Market Cap$272M
5Y Perf.-81.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
REPL vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.83B
5Y Perf.+11.7%
REPL vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | REPL | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $272M | $5.83B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-315M | $-464M |
| Total Debt | $76M | $98K |
| Cash & Equiv. | $111M | $714M |
REPL vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
REPL
IMVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Replimune Group, In… (REPL) | 100 | 18.2 | -81.8% |
| Immunovant, Inc. (IMVT) | 100 | 111.7 | +11.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: REPL vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IMVT leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Replimune Group, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
REPL
Replimune Group, Inc.
The Income Pick
REPL is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.83
- EPS growth 5.2%
- Lower volatility, beta 0.83, Low D/E 18.3%, current ratio 7.95x
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 188.1% 10Y total return vs REPL's -77.4%
- -21.3% revenue growth vs REPL's -39.7%
- 3.2% margin vs REPL's 2.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMVT | -21.3% revenue growth vs REPL's -39.7% |
| Quality / Margins | IMVT | 3.2% margin vs REPL's 2.4% |
| Stability / Safety | REPL | Beta 0.83 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IMVT | +107.2% vs REPL's -54.4% |
| Efficiency (ROA) | IMVT | -44.1% ROA vs REPL's -94.4% |
REPL vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGREPL
REPLReplimune Group, Inc.
0leads
IMVTImmunovant, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs REPLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IMVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IMVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
REPL and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | REPLReplimune Group, … | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$323M | -$487M |
| Net IncomeAfter-tax profit | -$315M | -$464M |
| Free Cash FlowCash after capex | -$283M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +2.5% | +19.7% |
IMVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — REPL and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | REPLReplimune Group, … | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $272M | $5.8B |
| Enterprise ValueMkt cap + debt − cash | $237M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.11x | -10.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.66x | 6.14x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — REPL and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-150 for REPL. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to REPL's 0.18x.
| Metric | REPLReplimune Group, … | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -149.5% | -47.1% |
| ROA (TTM)Return on assets | -94.4% | -44.1% |
| ROICReturn on invested capital | -51.9% | — |
| ROCEReturn on capital employed | -55.9% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.18x | 0.00x |
| Net DebtTotal debt minus cash | -$35M | -$714M |
| Cash & Equiv.Liquid assets | $111M | $714M |
| Total DebtShort + long-term debt | $76M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | -48.62x | — |
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $17,386 today (with dividends reinvested), compared to $963 for REPL. Over the past 12 months, IMVT leads with a +107.2% total return vs REPL's -54.4%. The 3-year compound annual growth rate (CAGR) favors IMVT at 14.1% vs REPL's -42.6% — a key indicator of consistent wealth creation.
| Metric | REPLReplimune Group, … | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -61.6% | +10.7% |
| 1-Year ReturnPast 12 months | -54.4% | +107.2% |
| 3-Year ReturnCumulative with dividends | -81.1% | +48.4% |
| 5-Year ReturnCumulative with dividends | -90.4% | +73.9% |
| 10-Year ReturnCumulative with dividends | -77.4% | +188.1% |
| CAGR (3Y)Annualised 3-year return | -42.6% | +14.1% |
IMVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — REPL and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
REPL is the less volatile stock with a 0.83 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 95.3% from its 52-week high vs REPL's 25.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | REPLReplimune Group, … | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.83x | 1.37x |
| 52-Week HighHighest price in past year | $13.24 | $30.09 |
| 52-Week LowLowest price in past year | $1.50 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +25.8% | +95.3% |
| RSI (14)Momentum oscillator 0–100 | 40.1 | 55.7 |
| Avg Volume (50D)Average daily shares traded | 5.5M | 1.4M |
Evenly matched — REPL and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates REPL as "Buy" and IMVT as "Buy". Consensus price targets imply 265.5% upside for REPL (target: $13) vs 58.7% for IMVT (target: $46).
| Metric | REPLReplimune Group, … | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $12.50 | $45.50 |
| # AnalystsCovering analysts | 15 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallImmunovant, Inc. (IMVT)Leads 3 of 6 categories
Loading custom metrics...
REPL vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is REPL or IMVT a better buy right now?
Analysts rate Replimune Group, Inc.
(REPL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — REPL or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +73. 9%, compared to -90. 4% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: IMVT returned +188. 1% versus REPL's -77. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — REPL or IMVT?
By beta (market sensitivity over 5 years), Replimune Group, Inc.
(REPL) is the lower-risk stock at 0. 83β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 65% more volatile than REPL relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 18% for Replimune Group, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — REPL or IMVT?
On earnings-per-share growth, the picture is similar: Replimune Group, Inc.
grew EPS 5. 2% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — REPL or IMVT?
Replimune Group, Inc.
(REPL) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REPL leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — REPL leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — REPL or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is REPL or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Replimune Group, Inc.
(REPL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83)). Both have compounded well over 10 years (REPL: -77. 4%, IMVT: +188. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between REPL and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.